...
首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Microdialysis feasibility investigations with the non-hydrophilic antifungal voriconazole for potential applications in nonclinical and clinical settings.
【24h】

Microdialysis feasibility investigations with the non-hydrophilic antifungal voriconazole for potential applications in nonclinical and clinical settings.

机译:使用非亲水性抗真菌伏立康唑进行微透析的可行性研究可用于非临床和临床环境。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: This study aimed at investigating the feasibility and validity of the microdialysis technique for the non-hydrophilic antifungal voriconazole, in settings for established concentric and new linear catheters. Optimal conditions for application of microdialysis in in vivo studies including steady-state conditions were to be elaborated. MATERIALS AND METHODS: For in vitro microdialysis investigations, a robust and easy-to-handle system was developed permitting standardized physiological-like conditions. Various experiments on the influence of flow-rate (0.4 - 10.0 microl/min), voriconazole concentration (1.0 - 50.0 microg/ml) on relative recovery were performed. Additionally, the mass transfer coefficient r of voriconazole was estimated (WinNonlin). RESULTS: In vitro microdialysis experiments suggested sufficient voriconazole concentrations in the dialysate for (non-)clinical investigations. The stability of voriconazole was confirmed over 10 h (37 degrees C). A flow-rate dependency was shown (optimum: 2.0 microl/min) and r was estimated to be 0.09 mm/min and 0.11 mm/min for concentric and linear catheters, respectively. Relative recovery in delivery/recovery experiments was independent of the voriconazole concentration ranging from 96.0% to 97.8%/93.8% to 100.2% (CV 1.7%/ 0.5%) indicating unhampered passage of voriconazole through the catheter. Investigations mimicking steady-state suggested voriconazole concentration of 100 - 200 microg/ml for in vivo catheter calibration solutions. CONCLUSION: The results demonstrate the feasibility and validity of the microdialysis technique in clinically-mimicked settings despite the higher lipophilicity of voriconazole and support the application of the technique in vivo.
机译:目的:本研究旨在探讨微透析技术用于非亲水性抗真菌伏立康唑的可行性和有效性,该技术适用于已建立的同心和新型线性导管。将详细阐述在体内研究中应用微透析的最佳条件,包括稳态条件。材料与方法:为了进行体外微透析研究,开发了一种强大且易于操作的系统,可实现标准化的类似生理的条件。进行了各种实验,研究了流速(0.4-10.0微升/分钟),伏立康唑浓度(1.0-50.0微克/毫升)对相对回收率的影响。另外,估算了伏立康唑的传质系数r(WinNonlin)。结果:体外微透析实验表明,伏立康唑在透析液中的浓度足以用于(非)临床研究。确认伏立康唑的稳定性超过10小时(37摄氏度)。显示了流速依赖性(最佳:2.0微升/分钟),同心和线性导管的r分别估计为0.09 mm / min和0.11 mm / min。递送/回收实验中的相对回收率与伏立康唑的浓度无关,范围为96.0%至97.8%/ 93.8%至100.2%(CV 1.7%/ 0.5%),表明伏立康唑无阻碍地通过导管。模仿稳态的研究表明,体内导管校准溶液的伏立康唑浓度为100-200微克/毫升。结论:尽管伏立康唑具有更高的亲脂性,但该结果证明了微透析技术在临床模拟环境中的可行性和有效性,并支持该技术在体内的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号